High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it designated Michael Buckner as Chief Legal Officer, having previously served at Danaher as Vice President, Deputy General Counsel, and Chief M&A Counsel. Mr. Buckner has nearly 30 years of experience as a senior global legal executive with experience in complex transactions and regulatory environments, the […]
This company, which has raised its dividend for 54 consecutive years, is on sale.
Abbott Laboratories (NYSE:ABT) is one of the best medical device stocks to invest in right now. Abbott Laboratories (NYSE:ABT) announced on April 28 that it received the U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software. Management stated that the milestone marks a considerable step forward for the […]
April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its
Earlier this week, Abbott received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography platform that integrates high‑resolution coronary imaging with automated insights to guide stent sizing and placement in complex percutaneous coronary interventions. This positions Abbott at the forefront of AI-guided cardiovascular care, potentially making OCT a more intuitive, workflow-friendly tool for treating challenging coronary disease cases. Next, we’ll...
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.